|Phase III||Treatment||Completed||18 and over||NCI, Other||CDR0000306463|
RATIONALE: Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen containing cisplatin is most effective in treating cervical cancer.
PURPOSE: This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix.
Further Study Information
- Compare the survival and response of patients with stage IVB, recurrent, or persistent carcinoma of the cervix when treated with paclitaxel and cisplatin vs vinorelbine and cisplatin vs gemcitabine and cisplatin vs topotecan and cisplatin.
- Compare the toxic effects of these regimens in these patients.
- Compare the quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 4 treatment arms.
- Arm I: Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
- Arm II: Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
- Arm III: Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
- Arm IV: Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
In all arms, treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, before courses 2 and 5, and at 9 months after study entry.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 600 patients (150 per treatment arm) will be accrued for this study within 4 years.
- Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
- Stage IVB, recurrent, or persistent disease
- Not amenable to curative surgery and/or radiotherapy
- At least 1 unidimensionally measurable lesion
- At least 20 mm by palpation, plain x-ray, CT scan, or MRI OR at least 10 mm by spiral CT scan
- Biopsy confirmation required if lesion is less than 30 mm
- Target lesion must be outside of a previously irradiated field
- No craniospinal metastases
- 18 and over
- GOG 0-1
- Not specified
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Bilirubin no greater than 1.5 times normal
- Alkaline phosphatase no greater than 3 times normal
- AST no greater than 3 times normal
- Creatinine ≤ 1.2 mg/dL OR
- Creatinine > 1.2 mg/dL but < 1.5 mg/dL AND creatinine clearance ≥ 50 mL/min
- No bilateral hydronephrosis not alleviated by ureteral stents or percutaneous drainage
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer
- No prior malignancy whose treatment contraindicates the current study therapy
- No concurrent clinically significant infection
PRIOR CONCURRENT THERAPY:
- No concurrent cytokines
- At least 6 weeks since prior chemoradiotherapy and recovered
- No prior chemotherapy (except when concurrently administered with radiotherapy)
- Not specified
- See Disease Characteristics
- See Chemotherapy
- At least 3 weeks since prior radiotherapy and recovered
- Recovered from prior surgery
Trial Lead Organizations/Sponsors
Gynecologic Oncology GroupNational Cancer Institute
|Bradley J. Monk||Study Chair|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00064077
ClinicalTrials.gov processed this data on March 16, 2014
Back to Top